Alisertib (MLN8237)

For research use only. Not for use in humans.

目录号：S1133 中文名称：阿利色替

CAS No. 1028486-01-2

Alisertib (MLN8237)是一种选择性Aurora A抑制剂，无细胞试验中IC50为1.2 nM，作用于Aurora A比作用于Aurora B选择性强200倍以上。Alisertib 可诱导细胞周期阻滞、细胞凋亡与自噬。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1375.12	现货
5mg	RMB 983.87	现货
10mg	RMB 1725.78	现货
50mg	RMB 5505.84	现货
200mg	RMB 14496.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Alisertib (MLN8237)发表文献254篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 574(7777):268-272

PubMed: 31578521 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Med, 2016, 22(7):744-53

PubMed: 27213815 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

EMBO Rep, 2021, e51902

PubMed: 34169630 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

PLoS Genet, 2021, 17(4):e1009327

PubMed: 33901174 ( click the link to review the publication )

Neoplasia, 2021, 23(6):624-633

PubMed: 34107377 ( click the link to review the publication )

Am J Cancer Res, 2021, 11(6):3240-3251

PubMed: 34249458 ( click the link to review the publication )

Sci Rep, 2021, 11(1):10461

PubMed: 34002003 ( click the link to review the publication )

Mol Pharmacol, 2021, 99(6):435-447

PubMed: 33795352 ( click the link to review the publication )

Cancer Commun (Lond), 2021, 10.1002/cac2.12125

PubMed: 33471959 ( click the link to review the publication )

Mol Cell Endocrinol, 2021, 528:111243

PubMed: 33716050 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01019-9

PubMed: 33409897 ( click the link to review the publication )

Sci Rep, 2021, 11(1):2616

PubMed: 33510346 ( click the link to review the publication )

EMBO Rep, 2021, e51030

PubMed: 33615693 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

J Clin Invest, 2020, 139080

PubMed: 33016928 ( click the link to review the publication )
Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Oncogene, 2020, 16

PubMed: 32300176 ( click the link to review the publication )

Cancer Lett, 2020, 495:135-144

PubMed: 32979462 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2498

PubMed: 32899210 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32235770 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(10):3406-3414

PubMed: 33163279 ( click the link to review the publication )

Mol Cancer Res, 2020, 8

PubMed: 32269073 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.1226.2019

PubMed: 32591441 ( click the link to review the publication )

Front Oncol, 2020, 10:1354

PubMed: 32974133 ( click the link to review the publication )

J Cell Sci, 2020, 133(24)jcs240267

PubMed: 33376154 ( click the link to review the publication )

Dis Model Mech, 2020, dmm.44289

PubMed: 32571902 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15901

PubMed: 32954665 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(18)E6690

PubMed: 32932728 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Cancer Res, 2020, 80(16):3424-3435

PubMed: 32595135 ( click the link to review the publication )

J Cancer, 2020, 11(8):2241-2251

PubMed: 32127951 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:857

PubMed: 33042987 ( click the link to review the publication )

Cancer Lett, 2020, 491:50-59

PubMed: 32735909 ( click the link to review the publication )

CU Digital Repository, 2020, N/A

PubMed: N/A ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa570

PubMed: 32652013 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3485

PubMed: 31375684 ( click the link to review the publication )
Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5566

PubMed: 31804482 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2208

PubMed: 31101817 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3430-3442

PubMed: 30755439 ( click the link to review the publication )

Dev Cell, 2019, 50(3):355-366e6

PubMed: 31303441 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Rep, 2019, 26(2):293-301e7

PubMed: 30625311 ( click the link to review the publication )

Oncogene, 2019, 38(1):73-87

PubMed: 30082913 ( click the link to review the publication )

EBioMedicine, 2019, 41:120-133

PubMed: 30799199 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):881

PubMed: 31754113 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):606

PubMed: 31406104 ( click the link to review the publication )

FASEB J, 2019, 33(4):4866-4882

PubMed: 30596512 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.003

PubMed: 31257184 ( click the link to review the publication )

Curr Biol, 2019, 29(21):3563-3578

PubMed: 31668617 ( click the link to review the publication )

PLoS Negl Trop Dis, 2019, 13(5):e0007425

PubMed: 31095613 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(3):312-323

PubMed: 30485161 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2211

PubMed: 30778113 ( click the link to review the publication )

Int J Oncol, 2019, 55(4):938-948

PubMed: 31485600 ( click the link to review the publication )
Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2019, 41(6):e359-e370

PubMed: 30702467 ( click the link to review the publication )

Target Oncol, 2019, 14(5):563-575

PubMed: 31429028 ( click the link to review the publication )

Oncotarget, 2019, 10(17):1649-1659

PubMed: 30899434 ( click the link to review the publication )

Oncogene, 2019, 38(40):6696-6710

PubMed: 31391550 ( click the link to review the publication )

Blood Adv, 2019, 3(21):3214-3227

PubMed: 31698452 ( click the link to review the publication )

J Vis Exp, 2019, (151)

PubMed: 31589210 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Curr Biol, 2018, 28(21):3458-3468e5

PubMed: 30415701 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6594-6610

PubMed: 30181387 ( click the link to review the publication )

J Cell Biol, 2018, 217(1):107-116

PubMed: 29074706 ( click the link to review the publication )

Elife, 2018, doi: 107554/eLife38111

PubMed: 30070631 ( click the link to review the publication )

Thyroid, 2018, doi: 101089/thy20180183

PubMed: 30226440 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Oncogene, 2018, 37(22):2921-2935

PubMed: 29515234 ( click the link to review the publication )

Oncogene, 2018, 37(4):502-511

PubMed: 28967900 ( click the link to review the publication )

BMC Biol, 2018, 16(1):116

PubMed: 30336771 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):781

PubMed: 30013101 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2575-2585

PubMed: 30266802 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

Pharmacol Res, 2018, 134:166-178

PubMed: 29944980 ( click the link to review the publication )

Mol Pharm, 2018, 15(8):3046-3059

PubMed: 29863884 ( click the link to review the publication )
Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Apoptosis, 2018, 23(9-10):492-511

PubMed: 30027525 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

J Cancer, 2018, 9(12):2061-2071

PubMed: 29937924 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Int J Mol Med, 2018, 41(6):3629-3641

PubMed: 29512701 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):1206-1210

PubMed: 29845253 ( click the link to review the publication )

Anticancer Res, 2018, 38(6):3471-3476

PubMed: 29848699 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35875-35890

PubMed: 30542505 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14017

PubMed: 30228302 ( click the link to review the publication )

Oncotarget, 2018, 9(16):12769-12780

PubMed: 29560108 ( click the link to review the publication )

SLAS Discov, 2018, 23(8):850-861

PubMed: 29742358 ( click the link to review the publication )

J Neurooncol, 2018, 137(3):481-492

PubMed: 29396807 ( click the link to review the publication )

R Soc Open Sci, 2018, 5(12):181303

PubMed: 30662739 ( click the link to review the publication )

Sci Transl Med, 2017, 9(372)

PubMed: 28077684 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8:14294

PubMed: 28220783 ( click the link to review the publication )

Clin Cancer Res, 2017, 10.1158/1078-0432

PubMed: 28073841 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3571-3590

PubMed: 28972102 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 27593935 ( click the link to review the publication )

EBioMedicine, 2017, 24:43-55

PubMed: 29030058 ( click the link to review the publication )
Plant Physiol, 2017, 173(1):582-599

PubMed: 27879390 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(1):94-107

PubMed: 28848145 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28615297 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2552-2562

PubMed: 28847989 ( click the link to review the publication )

Eur J Med Chem, 2017, 140:1-19

PubMed: 28918096 ( click the link to review the publication )

Cell Discov, 2017, 3:16049

PubMed: 28101375 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(6):670-682

PubMed: 28235899 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

J Cell Sci, 2017, 130(4):683-688

PubMed: 28069833 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )

J Biol Chem, 2017, 292(5):1910-1924

PubMed: 28028179 ( click the link to review the publication )

Am J Transl Res, 2017, 9(10):4652-4672

PubMed: 29118925 ( click the link to review the publication )

Am J Transl Res, 2017, 9(3):845-873

PubMed: 28386317 ( click the link to review the publication )

BMC Cell Biol, 2017, 18(1):33

PubMed: 29141582 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(4):386-401

PubMed: 27396604 ( click the link to review the publication )

Oncotarget, 2017, 8(10):16669-16689

PubMed: 28035071 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(19):32117-32133

PubMed: 28389630 ( click the link to review the publication )

Sci Rep, 2017, 7(1):17978

PubMed: 29269934 ( click the link to review the publication )

Oncotarget, 2017, 8(68):112313-112329

PubMed: 29348827 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19738-19759

PubMed: 28160569 ( click the link to review the publication )

Oncotarget, 2017, 8(41):69691-69708

PubMed: 29050234 ( click the link to review the publication )
Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 8(59):100326-100338

PubMed: 29245981 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114474-114480

PubMed: 29383095 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19478-19490

PubMed: 28061448 ( click the link to review the publication )

Oncotarget, 2017, 8(54):92926-92942

PubMed: 29190967 ( click the link to review the publication )

Pharmaceuticals (Basel), 2017, 10(3)

PubMed: 29036881 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

Nat Commun, 2016, 7:11389

PubMed: 27091106 ( click the link to review the publication )

Nat Commun, 2016, 7:12674

PubMed: 27624869 ( click the link to review the publication )

Elife, 2016, 5:e11402

PubMed: 26878753 ( click the link to review the publication )

J Med Chem, 2016, 59(15):7188-211

PubMed: 27391133 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2135

PubMed: 26962685 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(8):1574-87

PubMed: 26908596 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(12):3400-3411

PubMed: 27768280 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Cell Biochem, 2016, 117(6):1340-51

PubMed: 26529125 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):566-76

PubMed: 27082306 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):413-24

PubMed: 26713495 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:3473-84

PubMed: 27366084 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 475(3):251-6

PubMed: 27233613 ( click the link to review the publication )
Exp Hematol, 2016, 44(4):247-56

PubMed: 26724640 ( click the link to review the publication )

Mol Med Rep, 2016, 14(1):394-8

PubMed: 27177156 ( click the link to review the publication )

Biol Bull, 2016, 231(1):61-72

PubMed: 27638695 ( click the link to review the publication )

Oncotarget, 2016, 7(22):33152-64

PubMed: 27121204 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84718-84735

PubMed: 27713168 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

J Cell Biol, 2015, 210(1):45-62

PubMed: 26124292 ( click the link to review the publication )

Mol Cancer, 2015, 14(1):83

PubMed: 25889801 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(9):2292-2300

PubMed: 25848977 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: 25395580 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):527-40

PubMed: 25501809 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):516-26

PubMed: 25501815 ( click the link to review the publication )

J Cell Sci, 2015, 128(20):3769-80

PubMed: 26349807 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: ( click the link to review the publication )

Int J Mol Sci, 2015,

PubMed: 26729093 ( click the link to review the publication )

Breast Cancer Res Tr, 2015, 149(3):715-26

PubMed: 25667100 ( click the link to review the publication )

Cell Cycle, 2015, 14(24):3908-19

PubMed: 26697841 ( click the link to review the publication )

Cell Cycle, 2015, 14(9):1447-58

PubMed: 25789545 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:1555-84

PubMed: 25792811 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:575-601

PubMed: 25632225 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )
Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(34):35247-62

PubMed: 26497213 ( click the link to review the publication )

Clin Cancer Res, 2014, 34(5):2269-74

PubMed: 24778030 ( click the link to review the publication )

Oncogene, 2014, 33(42):4985-96

PubMed: 24166501 ( click the link to review the publication )

Oncogene, 2014, 33(27):3550-60

PubMed: 23955083 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(5):797-811

PubMed: 25074669 ( click the link to review the publication )

Mol Oncol, 2014, 8(8):1419-28

PubMed: 24953013 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2719-2729

PubMed: 25090971 ( click the link to review the publication )

J Transl Med, 2014, 12(1):200

PubMed: 25082261 ( click the link to review the publication )

Mol Carcinog, 2014, 10.1002/mc.22223

PubMed: 25284017 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

FEBS Lett, 2014, 588(14):2198-205

PubMed: 24857377 ( click the link to review the publication )

Chembiochem, 2014, 15(3):443-50

PubMed: 24403173 ( click the link to review the publication )

PLoS One, 2014, 9(12):e113989

PubMed: 25436453 ( click the link to review the publication )

PLoS One, 2014, 9(3):e92402

PubMed: 24642638 ( click the link to review the publication )

PLoS One, 2014, 9(12):e116048

PubMed: 25545367 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101222

PubMed: 24983972 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )
PLoS One, 2014,

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):845-51

PubMed: 25218503 ( click the link to review the publication )

Neurosci Lett, 2014, 583:199-204

PubMed: 25263789 ( click the link to review the publication )

J Pediatr Surg, 2014, 49(1):159-65

PubMed: 24439602 ( click the link to review the publication )

Oncotarget, 2014, 5(10):2947-61

PubMed: 24930769 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4071-86

PubMed: 24901229 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6229-42

PubMed: 25153724 ( click the link to review the publication )

Nat Commun, 2013, 4:2656

PubMed: 24141283 ( click the link to review the publication )

EMBO Mol Med, 2013, 5(1):149-66

PubMed: 23180582 ( click the link to review the publication )

Leukemia, 2013, 27(3):560-8

PubMed: 22940834 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(19):E1779-87

PubMed: 23610398 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

J Cell Biol, 2013, 202(3):463-78

PubMed: 23918938 ( click the link to review the publication )

EMBO Rep, 2013, 14(9):829-36

PubMed: 23887685 ( click the link to review the publication )

Int J Cancer, 2013, 135(3):751-62

PubMed: 24382688 ( click the link to review the publication )

Oral Oncol, 2013, 49(6):551-9

PubMed: 23481312 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(7):1451-9

PubMed: 23597309 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 6):1355-65

PubMed: 23345402 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 9):2102-13

PubMed: 23532825 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1833(10):2220-32

PubMed: 23707954 ( click the link to review the publication )

Epigenetics Chromatin, 2013, 6(1):21

PubMed: 23829974 ( click the link to review the publication )

J Biol Chem, 2013, 289(1):74-88

PubMed: 24273164 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64306

PubMed: 23717592 ( click the link to review the publication )
PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23328114 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27670-81

PubMed: 22753416 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 135(2):433-44

PubMed: 22825030 ( click the link to review the publication )

Cell Cycle, 2012, 11(2):296-309

PubMed: 22214762 ( click the link to review the publication )

Cell Cycle, 2012, 11(13):2567-77

PubMed: 22722494 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30734

PubMed: 22359551 ( click the link to review the publication )

EMBO J, 2011, 30(5):906-19

PubMed: 21297582 ( click the link to review the publication )

Mol Cancer, 2011, 10:131

PubMed: 22011530 ( click the link to review the publication )

Oncotarget, 2011,

PubMed: 21865609 ( click the link to review the publication )

J Cell Biol, 2010, 191(7):1315-32

PubMed: 21187329 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):977-84

PubMed: 21072059 ( click the link to review the publication )

ACS Chem Biol, 2010, 5(6):563-76

PubMed: 20426425 ( click the link to review the publication )

Expert Opin Emerg Dr, 2010, 15(4):615-34

PubMed: 20690888 ( click the link to review the publication )

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述

特性

MLN8237 是第一个口服有效的小分子Aurora A激酶选择性抑制剂。

靶点

Aurora A ^[1]
(Cell-free assay)

1.2 nM

体外研究

MLN8237作用于Aurora A选择性比作用于结构相关的Aurora B 高200多倍，IC50为396.5 nM, 而对205种其他激酶则没有显著活性。^[1] 0.5 μM MLN8237处理MM1.S和 OPM1 细胞，抑制 Aurora A磷酸化，而不影响 Aurora B调节的组蛋白H3磷酸化。MLN8237作用于多发性骨髓瘤(MM) 细胞系，显著抑制细胞增殖，IC50为0.003-1.71 μM。在BM 基质细胞，IL-6和 IGF-1 存在时，MLN8237作用于原代MM 细胞和MM细胞系，抗增殖活性比只有MLN8237单独作用时高很多。0.5 μM MLN8237 作用于原代MM细胞和细胞系，使G2/M 期细胞提高2到6倍，且显著诱导凋亡和衰老，涉及p53, p21 和p27的上调,及 PARP,caspase 3,和 caspase 9的裂解。此外, MLN8237和 Dexamethasone联用具有协同作用，具有强抗MM 功效, 而和Doxorubicin 及Bortezomib联用则具有另外的功能。^[2] 0.5 μM MLN8237处理 FLO-1, OE19, 和OE33 食管腺癌细胞系，抑制集落形成，且显著提高多倍体细胞百分数,随后提高G1期细胞百分数,而与 Cisplatin (2.5 μM)联用则效果进一步提高，与单独用药相比，诱导产生更多, TAp73β, PUMA, NOXA, cleaved caspase-3, 和cleaved PARP。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT116	NXjwbnp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWewMlUh\|ryP	MX23NkBp	NUWwUJdOTE2VTx?=	NGPTSJBKSzVyPUCuNFQh\|ryP	NWXsVVBQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|Y3QDRpPkK2NVM3Pjh2PD;hQi=>
LS174T	NIL3TnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\2XVAvPSEQvF2=	M1u4U\|czKGh?	MVLEUXNQ	NVHCT2NjUUN3ME2wMlA2KM7:TR?=	MmTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
T84	M4nPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXOcFZQOC53IN88US=>	MnXtO\|IhcA>?	MX3EUXNQ	MXvJR\|UxRTBwMEmg{txO	NHLuNZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
LS180	M1vHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nPVVAvPSEQvF2=	MX63NkBp	NEH6XoFFVVOR	Ml3UTWM2OD1zIN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|Nk[4OEc,OjZzM{[2PFQ9N2F-
SW948	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTY[GdCOC53IN88US=>	M1;K[VczKGh?	NWrldlBkTE2VTx?=	NGnJfopKSzVyPUGg{txO	MorJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
HCT15	M{DjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVKwMlUh\|ryP	MVm3NkBp	MVHEUXNQ	MWHJR\|UxRDBwNDFOwG0>	M1LkfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2Olg1Lz5{NkGzOlY5PDxxYU6=
DLD-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LCV\|AvPSEQvF2=	M{HYelczKGh?	MXjEUXNQ	NV\PcpIzUUN3MEywMlgh\|ryP	M1nQfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2Olg1Lz5{NkGzOlY5PDxxYU6=
MIP-101	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVmwMlUh\|ryP	MnfWO\|IhcA>?	MYfEUXNQ	NEPu[4pKSzVyPUGg{txO	NEjuVFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
SNU1544	NH7yblVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3zZ3ZzOC53IN88US=>	MYK3NkBp	NXzq[lFkTE2VTx?=	MUjJR\|UxRTFizszN	NU[5N2ttRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|Y3QDRpPkK2NVM3Pjh2PD;hQi=>
OCI-Ly10	M{HBWGN6fG:2b4jpZ{BCe3OjeR?=		MWO3NkBp	MmS5SG1UVw>?	MWTJR\|UxRTBwMEW4JO69VQ>?	NVf1bZBGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
SU-DHL2	MlKxR5l1d3SxeHnjJGF{e2G7		NH:5PW84OiCq	NInIbYpFVVOR	M{jlUmlEPTB;MD6wNUDPxE1?	NWPkdYUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
OCI-LY7	MnPnR5l1d3SxeHnjJGF{e2G7		M2foXlczKGh?	MVLEUXNQ	MUHJR\|UxRTBwMEixJO69VQ>?	M1rQfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
SU-DHL6	MlX6R5l1d3SxeHnjJGF{e2G7		Mk\0O\|IhcA>?	NUjPSWJETE2VTx?=	MV;JR\|UxRTBwNEiyJO69VQ>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
Jeko-1	NIHuPXBEgXSxdH;4bYMhSXO\|YYm=		M3;Gb\|czKGh?	Mkj3SG1UVw>?	M2XvRmlEPTB;MD6wNlkh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
JVM-2	NVnzPHZpS3m2b4TvfIlkKEG\|c3H5		NY\wfZFFPzJiaB?=	NX\XUWFRTE2VTx?=	Ml;TTWM2OD1yLkCxJO69VQ>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
Rec-1	MVnDfZRwfG:6aXOgRZN{[Xl?		NXrGOYZYPzJiaB?=	M{LJcmROW09?	NFjrS5BKSzVyPUCuNFg4KM7:TR?=	NHvVRY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3PFM{OSd-MkW4O\|g{OzF:L3G+
Z-138	MX;DfZRwfG:6aXOgRZN{[Xl?		MX:3NkBp	M3;JWmROW09?	MYnJR\|UxRTBwMEGzJO69VQ>?	M2OzfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
H9	Mn3OR5l1d3SxeHnjJGF{e2G7		MVW3NkBp	MkPmSG1UVw>?	NYX2S4xsUUN3ME2wMlYh\|ryP	NXGxT4NuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
HH	NVH4WI5kS3m2b4TvfIlkKEG\|c3H5		M3TnNlczKGh?	MVvEUXNQ	M4nZUWlEPTB;MD63JO69VQ>?	MkO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
DND41	M13zVWN6fG:2b4jpZ{BCe3OjeR?=		NV3MZo9mPzJiaB?=	NFvGNYtFVVOR	NVLMVlFjUUN3ME2wMlEh\|ryP	NWnOeWtORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
CCL119	M2DkSWN6fG:2b4jpZ{BCe3OjeR?=		NEPFTYY4OiCq	MmXHSG1UVw>?	MXnJR\|UxRTBwME[yJO69VQ>?	M1Gy[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
J.Cam 1.6	NFroTnNEgXSxdH;4bYMhSXO\|YYm=		NVHPd2doPzJiaB?=	MYHEUXNQ	NF\FR3RKSzVyPUCuNVA2KM7:TR?=	NFzkXZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3PFM{OSd-MkW4O\|g{OzF:L3G+
Sup-T1	MWLDfZRwfG:6aXOgRZN{[Xl?		NVrXZWVXPzJiaB?=	MUfEUXNQ	NF\1cIVKSzVyPUKuNVQzKM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
Tib 152	MlHaR5l1d3SxeHnjJGF{e2G7		MXm3NkBp	MWPEUXNQ	NUeze5NMUUN3ME2wMlgh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
MCF7	NWG3dmg2TnWwY4Tpc44hSXO\|YYm=	NUfKWGprPSEQvF2=	Mn;pNlQhcA>?	MonTSG1UVw>?	M{e1Zmlv\HWlZYOgS\|IwVSCjcoLld5Q>	NV[4N4FNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MDA-MB-231	M4PlZmZ2dmO2aX;uJGF{e2G7	MWG1JO69VQ>?	M3O4cFI1KGh?	MmDKSG1UVw>?	MWnJcoR2[2W\|IFezM20h[XK{ZYP0	NIX5R5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MCF7	NWrzd3MyTnWwY4Tpc44hSXO\|YYm=	MkTBOUDPxE1?	MnW3NlQhcA>?	NXPQU\|dmTE2VTx?=	NVPCfXRnTGWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJGNFUzFxQ1TDNi=>	NVPTcpp{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MCF7	MWTGeY5kfGmxbjDBd5NigQ>?	NEO4N4o2KM7:TR?=	NULidY5LOjRiaB?=	M2LvU2ROW09?	M{jVVWRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz	MojnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MCF7	M4LLOWZ2dmO2aX;uJGF{e2G7	NIXaZ4Y2KM7:TR?=	MknONlQhcA>?	NIT2VnFFVVOR	MVTE[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MCF7	MVLGeY5kfGmxbjDBd5NigQ>?	NV;LOm9UPSEQvF2=	NHzZV2MzPCCq	M2LRc2ROW09?	NGTRVJJKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>?	NUK1O2prRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MCF7	NUTPTndOTnWwY4Tpc44hSXO\|YYm=	M2G1WVUh\|ryP	M2O5dVI1KGh?	MXzEUXNQ	NUXMS4F2UW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJJAzPyCNaYCx	NViz[W1HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MDA-MB-231	M12wXWZ2dmO2aX;uJGF{e2G7	NXLRcWgzPSEQvF2=	NGLO[ogzPCCq	MkLOSG1UVw>?	MlG4SIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET\|EwS0SFMh?=	NV[5NWNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MDA-MB-231	M2[1cGZ2dmO2aX;uJGF{e2G7	M{P2Z\|Eh\|ryP	MUOyOEBp	M2jkOmROW09?	M3GyUWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz	M3LZZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MDA-MB-231	NYX2VnBWTnWwY4Tpc44hSXO\|YYm=	MXe1JO69VQ>?	MYqyOEBp	MYTEUXNQ	M{\QeWRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDjfYNtcW5iQkG=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	MlXDSpVv[3Srb36gRZN{[Xl?	MmjROUDPxE1?	NXTWWlg4OjRiaB?=	NUTIPWhuTE2VTx?=	Ml\6TY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE>	NWD4OVFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MDA-MB-231	NGP2fohHfW6ldHnvckBCe3OjeR?=	NYjHbm1jPSEQvF2=	MnnmNlQhcA>?	M{DPcmROW09?	NEHiNZlKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG=	M3LzUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MDA-MB-231	MkXrSpVv[3Srb36gRZN{[Xl?	M{HPfFUh\|ryP	MV[yOEBp	NXrYXYF7TE2VTx?=	MYrJcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEWz	MlTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MCF7	Mn;lRZBweHSxc3nzJGF{e2G7	MmDlOUDPxE1?	MYeyOEBp	MoPvSG1UVw>?	MlX2TY5lfWOnczDhdI9xfG:2aXOg[IVifGh?	NFKzWos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MDA-MB-231	NHfOcHVCeG:ydH;zbZMhSXO\|YYm=	M{XvTlUh\|ryP	NH;2b\|IzPCCq	MmHLSG1UVw>?	MmL0TY5lfWOnczDhdI9xfG:2aXOg[IVifGh?	NXnyeWFDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MCF7	NXv5fXRYTnWwY4Tpc44hSXO\|YYm=	NIHNNowyKM7:TR?=	MXu3NkBp	NUfIT5g2TE2VTx?=	MULJcoR2[2W\|IHH1eI9xcGGpaXOg[IVifGh?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	MUXGeY5kfGmxbjDBd5NigQ>?	NWDOZlJoOSEQvF2=	MmjuO\|IhcA>?	M1HtZWROW09?	MlTMTY5lfWOnczDheZRweGijZ3njJIRm[XSq	NULkS\|VTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
U-2 OS	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13BdFUxKM7:TR?=	MmS1NlQhcA>?	NILGS49FVVOR	NUPvO2pIUUN3ME2xOk43KM7:TR?=	NXPUTZdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVI5OTFpPkK1O\|kzQDFzPD;hQi=>
MG-63	MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nkcVUxKM7:TR?=	NVjtfYNwOjRiaB?=	M3HW[GROW09?	MVXJR\|UxRTlwNTFOwG0>	NIi3NJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NlgyOSd-MkW3PVI5OTF:L3G+
U-2 OS	M3ztOmFxd3C2b4Ppd{BCe3OjeR?=	NFfzZZE2KM7:TR?=	NYT1UYpnOjRiaB?=	NELw[WxFVVOR	NVfGRWNTUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>?	M3HIelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{myPFEyLz5{NUe5NlgyOTxxYU6=
MG-63	NGG1NZZCeG:ydH;zbZMhSXO\|YYm=	M3fNZ\|Uh\|ryP	MmW2NlQhcA>?	MWfEUXNQ	NVToTIRnUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>?	Ml[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUK4NVEoRjJ3N{myPFEyRC:jPh?=
U-2 OS	NFPsPZBHfW6ldHnvckBCe3OjeR?=	MWC1JO69VQ>?	MYCyOEBp	MULEUXNQ	MX\Qdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg>	M1zyfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{myPFEyLz5{NUe5NlgyOTxxYU6=
MG-63	MVnGeY5kfGmxbjDBd5NigQ>?	Mn\POUDPxE1?	NGm2[YczPCCq	NUfqW25lTE2VTx?=	MWjQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg>	NXjiO3FmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVI5OTFpPkK1O\|kzQDFzPD;hQi=>
PANC-1	NX3PVJJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zwWVUxKM7:TR?=	MU[yOEBp	NInUSIpFVVOR	M{LWcWlEPTB;Nz6xJO69VQ>?	M122VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkOyNlI2Lz5{NU[zNlIzPTxxYU6=
BxPC-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvEWVk2OCEQvF2=	MXWyOEBp	NFvWWpJFVVOR	NYq0Wo9rUUN3ME22Mlgh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|MkKyOUc,OjV4M{KyNlU9N2F-
PANC-1	M{XsNWZ2dmO2aX;uJGF{e2G7	MVO1JO69VQ>?	MoXqNlQhcA>?	MnLPSG1UVw>?	Ml6yTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dDDpckBIOi:PIIDoZZNm	M4rGb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkOyNlI2Lz5{NU[zNlIzPTxxYU6=
BxPC-3	NGXYcpBHfW6ldHnvckBCe3OjeR?=	NVHIU\|diPSEQvF2=	NELBR5QzPCCq	M3\lZ2ROW09?	MkLpTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dDDpckBIOi:PIIDoZZNm	NFP0PZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzPSd-MkW2N\|IzOjV:L3G+
PANC-1	NFzWdnNHfW6ldHnvckBCe3OjeR?=	M3H3fFUh\|ryP	MV6yOEBp	MVzEUXNQ	NIn1dWhKdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>?	NVXFepFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjVpPkK1OlMzOjJ3PD;hQi=>
BxPC-3	M{DHeGZ2dmO2aX;uJGF{e2G7	NYr0VXdSPSEQvF2=	MVmyOEBp	MWfEUXNQ	NVLOV5NLUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|MkKyOUc,OjV4M{KyNlU9N2F-
SKOV3	MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NID4T2QyODBizszN	NHLaZYQzPCCq	M1LWPWROW09?	M2jsc2lEPTB;MkCuOFgh\|ryP	M3ywPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK0O\|UxLz5{NU[yOFc2ODxxYU6=
OVCAR4	M4CzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlP1NVAxKM7:TR?=	M1LES\|I1KGh?	M4X1bWROW09?	NILwOndKSzVyPUKyMlE{KM7:TR?=	M2rCW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK0O\|UxLz5{NU[yOFc2ODxxYU6=
SKOV3	NUH5fWpQTnWwY4Tpc44hSXO\|YYm=	Ml[0OUDPxE1?	M3XVN\|czKGh?	NWHOTpY2TE2VTx?=	MVTJcoR2[2W\|IFeyM20h[XK{ZYP0	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NEe1NEc,OjV4MkS3OVA9N2F-
OVCAR4	NILpRXNHfW6ldHnvckBCe3OjeR?=	MljTOUDPxE1?	MXS3NkBp	Ml7QSG1UVw>?	NEjqSHRKdmS3Y3XzJGczN01iYYLy[ZN1	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NEe1NEc,OjV4MkS3OVA9N2F-
SKOV3	MnHFRZBweHSxc3nzJGF{e2G7	MkXEOUDPxE1?	M2jDflI1KGh?	MWPEUXNQ	M3fRc2lv\HWlZYOgZZBweHSxc3nz	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NEe1NEc,OjV4MkS3OVA9N2F-
OVCAR4	MXzBdI9xfG:\|aYOgRZN{[Xl?	MkTZOUDPxE1?	M{TJS\|I1KGh?	NGTtc5ZFVVOR	NFfNZ3FKdmS3Y3XzJIFxd3C2b4Ppdy=>	MnnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkS3OVAoRjJ3NkK0O\|UxRC:jPh?=
AGS	MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkf4NlUh\|ryP	M1jQV\|I1KGh?	MXXEUXNQ	M4PNSWlEPTB;MUmuNFkh\|ryP	Mmf2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MEm5NlMoRjJ3NkC5PVI{RC:jPh?=
NCI-N78	NFzwbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1H5NVI2KM7:TR?=	NUG5dVZMOjRiaB?=	NUTvS5NzTE2VTx?=	MWHJR\|UxRTJ4LkOzJO69VQ>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZyOUmyN{c,OjV4MEm5NlM9N2F-
AGS	M2\PbWFxd3C2b4Ppd{BCe3OjeR?=	M4ftbVUh\|ryP	MoPWNlQhcA>?	M3HN[WROW09?	NYW4V\|RkUW6mdXPld{BieG:ydH;zbZM>	MkizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MEm5NlMoRjJ3NkC5PVI{RC:jPh?=
NCI-N78	M4rCTGFxd3C2b4Ppd{BCe3OjeR?=	MWO1JO69VQ>?	NIT3OYkzPCCq	MY\EUXNQ	M2LPfmlv\HWlZYOgZZBweHSxc3nz	M1vD[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkC5PVI{Lz5{NU[wPVkzOzxxYU6=
AGS	M{C3e2Z2dmO2aX;uJGF{e2G7	Mo\DOUDPxE1?	Mly4NlQhcA>?	MXfEUXNQ	NFPRd3FKdmS3Y3XzJJRp\SCjdYTvdIhi\3l?	NVTCWpJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NFk6OjNpPkK1OlA6QTJ\|PD;hQi=>
NCI-N78	NWLteIR6TnWwY4Tpc44hSXO\|YYm=	NFXiWZE2KM7:TR?=	M2CxdVI1KGh?	M2m2e2ROW09?	MkfITY5lfWOnczD0bIUh[XW2b4DoZYd6	NFe0W4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[wPVkzOyd-MkW2NFk6OjN:L3G+
HSC-3	M4HNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPxNUDPxE1?	NXG0THBtPDhiaB?=		NFzEWJZKSzVyPUCuOVQh\|ryP	NHrvXHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2OlE1Oyd-MkWzOlYyPDN:L3G+
GB30	NXnzWnNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUSxJO69VQ>?	NWrh[2xXPyCm	MoDQSG1UVw>?	MmriTWM2OD1yLkCxNUDPxE1?	NGrzNZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwOlQzQCd-MkWxNFY1Ojh:L3G+
GB9	MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGq2SJkyKM7:TR?=	NVO4[3lOPyCm	NYPQcFhWTE2VTx?=	NHv2PJdKSzVyPUCuNFI1KM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyNkSyPEc,OjVzME[0Nlg9N2F-
GB169	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\ZXIcyKM7:TR?=	NWD5e5U6PyCm	MX;EUXNQ	M4TDfmlEPTB;MD6wN\|Ih\|ryP	NGLTXY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwOlQzQCd-MkWxNFY1Ojh:L3G+
T24	NHfwR5RHfW6ldHnvckBCe3OjeR?=	MkDuNUDPxE1?	NGPCOHk1QCCq	M4q5fWROW09?	NGjKXJRKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0	M4i5SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NECzOlM{Lz5{M{SwN\|Y{OzxxYU6=
RT4	MWjGeY5kfGmxbjDBd5NigQ>?	MUWxJO69VQ>?	MoLROFghcA>?	MVPEUXNQ	M2m2PWlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyM{[zN{c,OjN2MEO2N\|M9N2F-
UM-UC-3	NGrpdWJHfW6ldHnvckBCe3OjeR?=	MVqxJO69VQ>?	NFTGclE1QCCq	NFTReXRFVVOR	M1\1fmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyM{[zN{c,OjN2MEO2N\|M9N2F-
T24	MoLJRZBweHSxc3nzJGF{e2G7	NEDmfow{NjF4IN88US=>	MnfBPVYhcA>?	NHy0RYdFVVOR	MXvJR\|UxRTBwMEOwOkDPxE1?	Mk\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MEO2N\|MoRjJ\|NECzOlM{RC:jPh?=
RT4	NUTWeXFiSXCxcITvd4l{KEG\|c3H5	NGD2VHo{NjF4IN88US=>	M3q0OFk3KGh?	MVLEUXNQ	NVi2fld3UUN3ME2wMlEyQThizszN	NH3V[lY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SwN\|Y{Oyd-MkO0NFM3OzN:L3G+
UM-UC-3	NGjpO\|JCeG:ydH;zbZMhSXO\|YYm=	NFzKSFQ{NjF4IN88US=>	MmKxPVYhcA>?	M1rYPWROW09?	Mnj3TWM2OD1yLkC0OFkh\|ryP	NVX5XYRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzNpPkKzOFA{PjN\|PD;hQi=>
OVCAR-5	M4LO[GZ2dmO2aX;uJGF{e2G7	NVrEVWVCPTBibl2=			MWrJcohq[mm2czDj[YxtKG2rZ4LheIlwdg>?	MoqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|M{SzNlcoRjJ\|M{O0N\|I4RC:jPh?=
SKOV3ip2	NYLqS5l7TnWwY4Tpc44hSXO\|YYm=	MoLzOVAhdk1?			NUi1fYt2UW6qaXLpeJMh[2WubDDtbYdz[XSrb36=	NVi0Zmd3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzN\|Q{OjdpPkKzN\|M1OzJ5PD;hQi=>
S462	MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PrUVExOCEQvF2=	MonlO\|IhcA>?	M1;BZWROW09?	MnfqRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>?	M{Plc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{K4NVE1Lz5{M{OyPFEyPDxxYU6=
2884	NFe3b2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzJemdPOTByIN88US=>	NETkUXY4OiCq	MlnpSG1UVw>?	MYDBeJRmdnWjdHXzJINmdGxiZ4Lve5Rp	Mn;lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MkixNVQoRjJ\|M{K4NVE1RC:jPh?=
2885	M2mwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:yNVAxKM7:TR?=	MWi3NkBp	MnXHSG1UVw>?	NGDrTJZCfHSnboXheIV{KGOnbHyg[5Jwf3Sq	M4X0e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{K4NVE1Lz5{M{OyPFEyPDxxYU6=
CRL-2396	NWXWZm5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYSxNFAh\|ryP		Mmm4e4F1\XJ?	M2jMU2lEPTB;MD6wPVIh\|ryP	M1\GZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUWzOVI1Lz5{M{G1N\|UzPDxxYU6=
TIB-48	M1Lye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfkNVAxKM7:TR?=		M4LBfpdifGW{	M{DFV2lEPTB;MD6wPFgh\|ryP	MkfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNUO1NlQoRjJ\|MUWzOVI1RC:jPh?=
CRL-2396	MVTDfZRwfG:6aXOgRZN{[Xl?	MU[xJO69VQ>?	NIP5dXA1QCCq	MlTne4F1\XJ?	M{[yNWlv\HWlZYOgZZBweHSxc3nz	NEn3V4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G1N\|UzPCd-MkOxOVM2OjR:L3G+
TIB-48	NIPXdYFEgXSxdH;4bYMhSXO\|YYm=	M134[FEh\|ryP	M{DpclQ5KGh?	NFv5TZZ4[XSnch?=	M{POO2lv\HWlZYOgZZBweHSxc3nz	NEXzdZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G1N\|UzPCd-MkOxOVM2OjR:L3G+
AGS	MXPDfZRwfG:6aXOgRZN{[Xl?	MWOwMlUh\|ryP	NF;4SWQzPCCq	MU\EUXNQ	MWXE[YNz\WG\|ZYOgZ4VtdCC\|dYL2bZZidA>?	NYXvOGhRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5O\|I3OTFpPkKyPVczPjFzPD;hQi=>
FLO-1	M2jhO2N6fG:2b4jpZ{BCe3OjeR?=	NYXxNWZ1OC53IN88US=>	M4jnelI1KGh?	NVPYVVZiTE2VTx?=	MlTsSIVkemWjc3XzJINmdGxic4Xyeol3[Wx?	MmfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7N{K2NVEoRjJ{OUeyOlEyRC:jPh?=
OE33	MVjDfZRwfG:6aXOgRZN{[Xl?	NYjJdGE3OC53IN88US=>	NF7NNJIzPCCq	NEHVUIJFVVOR	M1vJWGRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu	M1vxclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUeyOlEyLz5{Mkm3NlYyOTxxYU6=
SKLMS	M2PpW2N6fG:2b4jpZ{BCe3OjeR?=	M1rlO\|c2KG6P	MlTLPVYhcA>?		NWrXXYRVUW6mdXPld{BieG:ydH;zbZM>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{MUm5O{c,OjJ6MkG5PVc9N2F-
Leio285	M3LpOGN6fG:2b4jpZ{BCe3OjeR?=	NU[5bnpZPzVibl2=	MoTGPVYhcA>?		MUnJcoR2[2W\|IHHwc5B1d3Orcx?=	Ml60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MkG5PVcoRjJ{OEKxPVk4RC:jPh?=
Mes-Sa	MWfDfZRwfG:6aXOgRZN{[Xl?	NWjtOmhIPzVibl2=	NWTXdm1WQTZiaB?=		NVPhWZZGUW6mdXPld{BieG:ydH;zbZM>	MojTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MkG5PVcoRjJ{OEKxPVk4RC:jPh?=
DAOY	MkCyR5l1d3SxeHnjJGF{e2G7	NGLUT4syOCEQvF2=	MXW3NkBp	NFPxTI9FVVOR	MlzMTWM2OD1yLkC0JO69VQ>?	NEj4bHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[2PVM{PSd-MkK2Olk{OzV:L3G+
IMR32	Mm\ZR5l1d3SxeHnjJGF{e2G7	MkfsNVAh\|ryP	Moq5O\|IhcA>?	M4P5cmROW09?	M1i0SWlEPTB;MD6wN{DPxE1?	M37XbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Nk[5N\|M2Lz5{Mk[2PVM{PTxxYU6=
Molt-4	NVjXUlhjS3m2b4TvfIlkKEG\|c3H5	NUfQV4xpOTBizszN	Mnn5O\|IhcA>?	MorsSG1UVw>?	NVjKVFZCUUN3ME2wMlAzKM7:TR?=	Ml7RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NkmzN\|UoRjJ{Nk[5N\|M2RC:jPh?=
MOLM-13	NHjOTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPDN{DPxE1?	MUi3NkBp		NISyeYZFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	MlzrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEiyOFkoRjJ{NEi4NlQ6RC:jPh?=
HL-60	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TwUFMh\|ryP	MXi3NkBp		Mn3BSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?=	Mk\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEiyOFkoRjJ{NEi4NlQ6RC:jPh?=
MV4-11	M2XX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXZR3E{KM7:TR?=	NWPoeYx{PzJiaB?=		NH3DUIpFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	NFuwTpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
SKM-1	NHnubJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVWzJO69VQ>?	MVm3NkBp		NWniW2E2TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	MlziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEiyOFkoRjJ{NEi4NlQ6RC:jPh?=
SH2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWezJO69VQ>?	NGDlWIE4OiCq		MlvpSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?=	NHTDbWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
NOMO-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVWzJO69VQ>?	NUHUOWI2PzJiaB?=		M3Pj[mRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	NWC5RVNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFgzPDlpPkKyOFg5OjR7PD;hQi=>
OCL-AML2	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{juRVMh\|ryP	M1zKSlczKGh?		MnTmSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?=	NG\Rd\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
PL-21	NETBR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHON{DPxE1?	MUe3NkBp		M4D0bWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	NH7ZfHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
KG-1	M{XUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXqcWhIOyEQvF2=	Mo\mO\|IhcA>?		MWnEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	NETXc2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
A172	Mki4R5l1d3SxeHnjJGF{e2G7	MXOxNFAh\|ryP	MV[yOEBp	NXnjPXRKTE2VTx?=	MonVTWM2OD1yLkGyNEDPxE1?	NX73RVB4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|Q{QTlpPkKyNlc1Ozl7PD;hQi=>
U87	M3v5cGN6fG:2b4jpZ{BCe3OjeR?=	MkC0NVAxKM7:TR?=	Mn[yNlQhcA>?	MoKySG1UVw>?	MYjJR\|UxRTBwMUC1JO69VQ>?	MnW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{SzPVkoRjJ{Mke0N\|k6RC:jPh?=
U251	MmHFR5l1d3SxeHnjJGF{e2G7	Mnz4NVAxKM7:TR?=	NFO0RVkzPCCq	Mof4SG1UVw>?	MYrJR\|UxRTBwMUCwJO69VQ>?	Ml;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{SzPVkoRjJ{Mke0N\|k6RC:jPh?=
T98	Mn\jR5l1d3SxeHnjJGF{e2G7	M3HVb\|ExOCEQvF2=	MVGyOEBp	NHn3ZVFFVVOR	M1rjVGlEPTB;MD6xNlUh\|ryP	NV;2WllZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|Q{QTlpPkKyNlc1Ozl7PD;hQi=>
LN18	MnHQR5l1d3SxeHnjJGF{e2G7	M2nBUVExOCEQvF2=	M{HiPVI1KGh?	MVTEUXNQ	MWLJR\|UxRTBwMkGwJO69VQ>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
LN443	MVjDfZRwfG:6aXOgRZN{[Xl?	M36zNVExOCEQvF2=	MX2yOEBp	Mnj3SG1UVw>?	NVPPeYlrUUN3ME2wMlIzOCEQvF2=	M{jvWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mke0N\|k6Lz5{MkK3OFM6QTxxYU6=
HF66	NY\ITY93S3m2b4TvfIlkKEG\|c3H5	MXKxNFAh\|ryP	NInQXHgzPCCq	NVTtVpRiTE2VTx?=	MlKyTWM2OD1yLkKyOUDPxE1?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
HF2303	NH;p[G9EgXSxdH;4bYMhSXO\|YYm=	M{\KRVExOCEQvF2=	NEWxPVkzPCCq	NGnZ[FdFVVOR	NXzSfmdDUUN3ME2wMlA3OCEQvF2=	NVz6UopvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|Q{QTlpPkKyNlc1Ozl7PD;hQi=>
HF2359	M3LIO2N6fG:2b4jpZ{BCe3OjeR?=	NV[3TpVWOTByIN88US=>	MV[yOEBp	NUjZdIZmTE2VTx?=	M1;COGlEPTB;MD6wOlAh\|ryP	MoD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{SzPVkoRjJ{Mke0N\|k6RC:jPh?=
HF2414	M1zMXGN6fG:2b4jpZ{BCe3OjeR?=	NG\3SZIyODBizszN	Mn3pNlQhcA>?	NXLlTYN1TE2VTx?=	NGXtbJVKSzVyPUCuNFgxKM7:TR?=	M2[zNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mke0N\|k6Lz5{MkK3OFM6QTxxYU6=
A-673	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXSNVAh\|ryP	MVW5OkBp	MX\EUXNQ	M{fXfWlEPTB;MD6wN\|Ih\|ryP	NIXVV4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
TC-32	M1PrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXWxNEDPxE1?	NWnCbZc2QTZiaB?=	NGrMU2pFVVOR	NYDvZ\|VmUUN3ME2wMlA{QSEQvF2=	NWfUSHY{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
TC-71	NWjMVGtZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTSNVAh\|ryP	NI\z[Zc6PiCq	MYTEUXNQ	NETnPXhKSzVyPUCuNVAzKM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
SK-N-MC	NYfVbG9IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfxXlJuOTBizszN	NFmybW46PiCq	NX7DZ\|A4TE2VTx?=	NYO0ZppPUUN3ME2wMlA4OiEQvF2=	NHTnRpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-9	NHHpfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rwUVExKM7:TR?=	Mk\3PVYhcA>?	MWXEUXNQ	M13UfWlEPTB;MD6wNVgh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-10	NHLLVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfERXVVOTBizszN	NWLOeIl{QTZiaB?=	NUHtfmRITE2VTx?=	NYHVb\|FYUUN3ME2wMlA3OCEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-25	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrUVoQyOCEQvF2=	NVvYWWp{QTZiaB?=	MV3EUXNQ	MUTJR\|UxRTBwMU[4JO69VQ>?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-32	NWfjT5hVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7VbmIyOCEQvF2=	NFX4WVE6PiCq	MVzEUXNQ	Mon1TWM2OD1yLkGzOkDPxE1?	NVflcVZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-56	NGfwXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLCNVAh\|ryP	MojxPVYhcA>?	M3TkNWROW09?	MV3JR\|UxRTFyIN88US=>	NGDGbnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-258	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;6PJcyOCEQvF2=	M{f1SFk3KGh?	MlPVSG1UVw>?	MVXJR\|UxRTBwMUOyJO69VQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
COG-E-352	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWe0W5QyOTBizszN	NWGySHd5QTZiaB?=	NWTHclUzTE2VTx?=	NV7DdodrUUN3ME2wMlA1OyEQvF2=	M4WwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
CHLA-90	NE\HfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHP2R5UyOCEQvF2=	MVO5OkBp	Mn7LSG1UVw>?	NYDYTHhpUUN3ME2wMlA3OSEQvF2=	M13ZNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
CHLA-119	MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M12wZlExKM7:TR?=	MkHMPVYhcA>?	NWPrW5JHTE2VTx?=	NHX6XGhKSzVyPUCuNFIzKM7:TR?=	NY\E[nBqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-122	NYPWe4wzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIO4O4YyOCEQvF2=	MWm5OkBp	NHT2SWRFVVOR	NIXjNJRKSzVyPUCuNFE6KM7:TR?=	MnrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
CHLA-136	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVqxNEDPxE1?	MnPzPVYhcA>?	MX3EUXNQ	NHL5R4ZKSzVyPUCuNFM6KM7:TR?=	NIPXdY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-140	NVvUWWpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;SSXd4OTBizszN	Mln2PVYhcA>?	M1LQUWROW09?	MXfJR\|UxRTBwMEK2JO69VQ>?	NVi3cVEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
LA-N-6	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYixNEDPxE1?	Mk\hPVYhcA>?	MmDXSG1UVw>?	MoG1TWM2OD1yLkC1OEDPxE1?	NIPRcVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
NB-1643	NF\zWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPLNWUyOCEQvF2=	NH;OXnE6PiCq	MmD6SG1UVw>?	MY\JR\|UxRTBwMEO3JO69VQ>?	MoizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
NB-EBc1	NW\V[\|VxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYOxNEDPxE1?	M3vWd\|k3KGh?	NF\pfYpFVVOR	NX7vU2trUUN3ME2wMlA2OCEQvF2=	NX3iRW1tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SK-N-BE-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUexNEDPxE1?	NVzafpU3QTZiaB?=	NEi5bJJFVVOR	NXXNUmpsUUN3ME2wMlAzQCEQvF2=	M1fyZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
SK-N-BE-2	NUPtbZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NECwUWkyOCEQvF2=	NEXzcVc6PiCq	NX7HboFnTE2VTx?=	NGnsZmRKSzVyPUCuNFM3KM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
SMS-KAN	NGrER\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfxdnBUOTBizszN	NVPOVnhHQTZiaB?=	MV\EUXNQ	NVnhOIJCUUN3ME2wMlA{PCEQvF2=	NVjYNGpIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-KANR	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXOR\|EyOCEQvF2=	MWi5OkBp	NUCwS2ZOTE2VTx?=	M3vIVGlEPTB;MD6wNlYh\|ryP	NV\RXld{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-KCN	MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYO3[lBXOTBizszN	NYHPT4M3QTZiaB?=	NIix[mpFVVOR	NVixT2pZUUN3ME2wMlAyQSEQvF2=	NHTsU3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
SMS-KCNR	NHHMU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfBTWEyOCEQvF2=	NWLUPXhqQTZiaB?=	M{XRWWROW09?	M4XW[mlEPTB;MD6wNVAh\|ryP	Mk\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
SMS-LHN	NYXZdWVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWWxNEDPxE1?	NWjNNIp5QTZiaB?=	MnfSSG1UVw>?	NGnK[pFKSzVyPUCuNFMzKM7:TR?=	NWXZRZFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-MSN	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUexNEDPxE1?	MV25OkBp	NGfsXo9FVVOR	MkKyTWM2OD1yLkCyNkDPxE1?	NVvuS5I1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-SAN	MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXyxNEDPxE1?	NED0UZo6PiCq	M3vhbmROW09?	NWLoRnFJUUN3ME2wMlAzOCEQvF2=	NVHjN\|JsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
Granta-4	NXzwWnZ3S3m2b4TvfIlkKEG\|c3H5	NXTKSVRGOTBizszN	NVrvRoNzPyCm		MVzJR\|UxRTBwMESwJO69VQ>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ7MUi2O{c,OjF{OUG4Olc9N2F-
DB	NWTnO4lLS3m2b4TvfIlkKEG\|c3H5	MoLtNVAh\|ryP	NInQSHc4KGR?		NEnScGlKSzVyPUCuNFQzKM7:TR?=	MlXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{OUG4OlcoRjJzMkmxPFY4RC:jPh?=
RL	NXvhW3dqS3m2b4TvfIlkKEG\|c3H5	NVHMTJJoOTBizszN	NH\nVYw4KGR?		MXnJR\|UxRTBwMEG1JO69VQ>?	Mke0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{OUG4OlcoRjJzMkmxPFY4RC:jPh?=
K562	MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rhfVExKM7:TR?=	NEjwe5g6PiCq		NVXQNZBMUUN3ME2wMlA5PyEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB7MU[zN{c,OjFyOUG2N\|M9N2F-
LAMA-84	MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\ZNIEyOCEQvF2=	MoHQPVYhcA>?		M3L0d2lEPTB;MD6wOVch\|ryP	Ml\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOUG2N\|MoRjJzMEmxOlM{RC:jPh?=
MM15	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYO0JO69VQ>?	MWS3NkBp	M37tdGROW09?	NIX4U25KSzVyPUCuNVMh\|ryP	NHjWXlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO4Nlg1PCd-MkCzPFI5PDR:L3G+
OPM1	MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYS0JO69VQ>?	NWHVUW5mPzJiaB?=	M13WbmROW09?	M33PdWlEPTB;MD6wN{DPxE1?	MoThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
RPM1	NXz0UHZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYK0JO69VQ>?	M4Xz[VczKGh?	MoG1SG1UVw>?	NV7BU5IzUUN3ME2xNE4{OiEQvF2=	MmrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
INA6	M2nsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn63OEDPxE1?	M4\YU\|czKGh?	MXLEUXNQ	NYPHbndxUUN3ME2wMlAxOiEQvF2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN6Mki0OEc,OjB\|OEK4OFQ9N2F-
OPM2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkL3OEDPxE1?	NX;iV4tiPzJiaB?=	NXviN3ZJTE2VTx?=	MUnJR\|UxRTRwM{eg{txO	MlTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
MM1R	NYHHNXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljtOEDPxE1?	NHTiXGo4OiCq	M2nDZWROW09?	MWPJR\|UxRTFwNkig{txO	MonlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
DOX40	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTjV5U1KM7:TR?=	M1TrZ\|czKGh?	NF30WXJFVVOR	NEC5dmNKSzVyPUWuOFgh\|ryP	Ml7XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
LR5	NEXXUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1npe\|Qh\|ryP	MWe3NkBp	MX\EUXNQ	Mlr0TWM2OD1{LkWzJO69VQ>?	M{S2fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{iyPFQ1Lz5{MEO4Nlg1PDxxYU6=
U266	M3u0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fDN\|Qh\|ryP	NUTESlhYPzJiaB?=	MWrEUXNQ	Mk\pTWM2OD1zLkSzJO69VQ>?	M1;SXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{iyPFQ1Lz5{MEO4Nlg1PDxxYU6=
RD	M{TGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUWxNEDPxE1?	MV:5OkBp		NXfIfHQ5UUN3ME2wMlIzQCEQvF2=	NV;HN4lkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
Rh41	MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\XNVAh\|ryP	M2LuN\|k3KGh?		NFPYcYhKSzVyPUCuNFkxKM7:TR?=	M1ywdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
Rh30	M3\BUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjDPGQyOCEQvF2=	M{LK[Vk3KGh?		NYD5emhIUUN3ME2wMlI{OCEQvF2=	M1zneVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
BT-12	M4rYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\DblExKM7:TR?=	MVS5OkBp		Moi5TWM2OD1yLkC2NEDPxE1?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
CHLA-266	NIPYbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXz[IMyOCEQvF2=	MWS5OkBp		NHr0UYVKSzVyPUCuNFczKM7:TR?=	NX\CeZd[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
TC-71	NUK1SXNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1q5NFExKM7:TR?=	NV2wcVdWQTZiaB?=		MXjJR\|UxRTBwMUCyJO69VQ>?	NWjuS2VNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
SJ-GBM2	M1;XU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXhOnRrOTBizszN	NXnmcGQ1QTZiaB?=		MU\JR\|UxRTBwMEWwJO69VQ>?	M4X6XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
NALM-6	M1\BbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4[5PVExKM7:TR?=	M1\DNlk3KGh?		M2Dxb2lEPTB;MD6wOlIh\|ryP	NIH1PWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGwPFM{QCd-MkCxNFg{Ozh:L3G+
COG-LL-317	NVf2UnZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\NRXFiOTBizszN	M1jGfVk3KGh?		MlTyTWM2OD1yLkC0O{DPxE1?	Mk\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
RS4-11	NEPsWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVGxNEDPxE1?	NInVblg6PiCq		NYfWRlBGUUN3ME2wMlAyQCEQvF2=	MoX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
MOLT-4	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLkNVAh\|ryP	Mn\uPVYhcA>?		M2S4fmlEPTB;MD6wNlYh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
CCRF-CEM	M2fuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVqxNEDPxE1?	M1jLU\|k3KGh?		M2K5VGlEPTB;MD6wPVQh\|ryP	M3LKTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
Kasumi-1	M4LMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWmzZYE5OTBizszN	NUn3N5dtQTZiaB?=		M3vBVWlEPTB;MD6xNFMh\|ryP	NVXJZ4hSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
Karpas-299	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUGxNEDPxE1?	MXm5OkBp		NWHMXotHUUN3ME2wMlA{QCEQvF2=	NEjaUII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGwPFM{QCd-MkCxNFg{Ozh:L3G+
Ramos-RA1	MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vLVFExKM7:TR?=	M{Lablk3KGh?		NYr3UoRMUUN3ME2wMlEzPyEQvF2=	NV:zclB{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
GSS	NFPuNmhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MnXkO\|IhcHK\|		M{TNUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR2PTJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6wN\|kh\|ryPLh?=	NUDJcWVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
LU99A	NXHx[5BoSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1nUO\|czKGi{cx?=		MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyXOUnBJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6wOlIh\|ryPLh?=	NVzvb417RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
HL60	Mln2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEKyZYY4OiCqcoO=		MkL2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTE[wJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6wO\|Qh\|ryPLh?=	MnG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
LC2/ad	MlzDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NF7tfW84OiCqcoO=		M1rEW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTFOyM4FlKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDXV3Q5KGG\|c3H5MEBKSzVyIE2gNE4xPzdizszNMi=>	M3r3UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1OlE4Lz5{NU[yOVYyPzxxYU6=
MKN45	M1:0UWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWC3NkBpenN?		MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2NTkS1JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6wPVMh\|ryPLh?=	NGrPRZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
HCT116	NHzvSI1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M37INFczKGi{cx?=		NHvUSnJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgW3NVQCCjc4PhfUwhUUN3MDC9JFAvODl3IN88UU4>	NXe2RZo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
Lu116	MoC4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NET0Z\|g4OiCqcoO=		NEDj[ZhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFz1NVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDXV3Q5KGG\|c3H5MEBKSzVyIE2gNE4xQTdizszNMi=>	NHX6ZmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
NCI-H358	MUfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NI\xW2U4OiCqcoO=		M4rFU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{PThiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjFizszNMi=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
MIAPaCa2	M2jTdGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mmi3O\|IhcHK\|		M2ezXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVnBVIFE[TJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjF\|IN88UU4>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
PC14	MmjlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Ml73O\|IhcHK\|		MlvrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{G0JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6xO{DPxE1w	MlG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
HT-29	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXS3NkBpenN?		MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6zN{DPxE1w	NVHZRWNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
HCT15	M{DaVWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MkPzO\|IhcHK\|		NWmyNHV1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{Bi\nSncjC3NkBpenNiYomgW3NVQCCjc4PhfUwhUUN3MDC9JFAvPzRizszNMi=>	NFrsfo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
Sf9	NVzEb4x6TnWwY4Tpc44h[XO\|YYm=				MnG1R49ueGW2aYTpeoUhcW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBud3W\|ZTDheZJwemFia3nuZZNmKEFiZYjwdoV{e2WmIHnuJIlve2WldDDT[lkh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiQWTQMEBMcSB;IECuNFAxOyEQvF2u	NEPkNlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGwNVU3PCd-Mk[xNFE2PjR:L3G+
Sf9	M1jENGZ2dmO2aX;uJIF{e2G7				M4fweWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgcY92e2ViYYXyc5JiKGurbnHz[UBCKGW6cILld5Nm\CCrbjDpcpNm[3RiU3[5JINmdGy\|IIXzbY5oKGKrb4Tpck1IVFKUQWPMS{BieyC\|dXLzeJJifGViaX6gdJJme2WwY3Wgc4YhY2ejbX3hMVM{WF2DVGCsJGlEPTBiPTCwMlAxOSEQvF2u	NI\TPJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGwNVU3PCd-Mk[xNFE2PjR:L3G+
HCT116	NUnufZFPTnWwY4Tpc44h[XO\|YYm=				MVnJcohq[mm2aX;uJI9nKGG3cn;yZUBscW6jc3WgRUBifXSxcHjvd5Bpd3K7bHH0bY9vKGG2IGSyPFghcW5iaIXtZY4hUEOWMUG2JINmdGy\|IHL5JIludXWwb3\seY9z\XOlZX7j[UBidmGueYPpd{whUUN3MDC9JFAvODB5IN88UU4>	MoXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMEG1OlQoRjJ4MUCxOVY1RC:jPh?=
HCT116	NGW2foJEgXSxdH;4bYNqfHliYYPzZZk>				NYnBbGlCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHL5JGJz\FViaX7jc5Jxd3KjdHnvckBie3OjeTygS2k2OCB;IECuNFMh\|ryPLh?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFyMUW2OEc,OjZzMEG1OlQ9N2F-
HCT116	NH;TOYZHfW6ldHnvckBie3OjeR?=				MXzJcohq[mm2aX;uJI9nKGG3cn;yZUBscW6jc3WgRkBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCqaYP0c45mKEh\|IIDoc5NxcG:{eXzheIlwdiCkeTDpcY12dm:obIXvdoV{[2WwY3WgZY5idHm\|aYOsJGlEPTBiPTCxMlUh\|ryPLh?=	NGfYclU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGwNVU3PCd-Mk[xNFE2PjR:L3G+
BL21 (DE3) Rosetta	NEX4S\|lHfW6ldHnvckBie3OjeR?=		M4HVTFMxKG2rboO=		NI\O[GxKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgbJVu[W5iQYXyc5JiKEFia3nuZZNmKChzMkKgeI8hPDBicnXzbYR2\XNrIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiKFTFN{khWm:\|ZYT0ZUBk\WyuczD1d4lv\yCkaX;0bY56dGG2ZXSgV3RMOiC\|dXLzeJJifGViaX7jeYJifGWmIH\vdkA{OCCvaX7zJIJ6KEiWUl[gZZN{[XluIFnDOVAhRSByLkCwNFA1KM7:TT6=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7MUGzN{c,Ojd\|OUGxN\|M9N2F-
HeLa Kyoto	NGLicnpHfW6ldHnvckBie3OjeR?=		M2TwWFIxKGi{cx?=		MVXJcohq[mm2aX;uJI9nKEG3cn;yZUBDKGurbnHz[UBqdiCqdX3hckBJ\UyjIFv5c5RwKGOnbHzzJIF{e2W\|c3XkJIF{KGWoZnXjeEBwdiCmaYP0doljfXSrb36gc4YheGi\|cHjvMYhqe3SxbnWgTFMhe2W{MUCgcIV3\WxiaX7jeYJifGWmIH\vdkAzOCCqcoOsJGlEPTBiPTCwMlAxOTVizszNMi=>	NHLvPXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O5NVE{Oyd-MkezPVEyOzN:L3G+
HeLa Kyoto	MmnxSpVv[3Srb36gZZN{[Xl?		M1Lz[\|IxKGi{cx?=		NFjFeGhKdmirYnn0bY9vKG:oIFH1do9z[SCDIHvpcoF{\SCjdYTvdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejJ6ODDpckBpfW2jbjDI[WxiKEu7b4TvJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhOjBiaILzMEBKSzVyIE2gNE4xODZ5IN88UU4>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7MUGzN{c,Ojd\|OUGxN\|M9N2F-
multiple myeloma	MXHGeY5kfGmxbjDhd5NigQ>?				Mn\kV5VxeHKnc4Ppc44hd2ZiY3XscEBucXSxc3nzJIlvKGi3bXHuJI12dHSrcHzlJI16\WyxbXGgZ4VtdHNuIFnDOVAhRSByLkCwN{DPxE1w	NIDXfoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmxPFA6Pid-Mki5NVgxQTZ:L3G+
Calu6	NXfwd2hsSW62aYT1cY9zKGG\|c3H5	MoPqNlAhdWdxa3e=	NETsOWYzOSCmYYnz		MnnYRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ3HseVYh[2WubIOgfIVvd2e{YX\0[YQhcW5ibX;1d4Uh[XO\|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiMkCgcYcwc2duIIDvJIJq\CCjZH3pcol{fGW{ZXSg[o9zKDJzIHThfZM>	NWTDb2FERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNFE2PjRpPkK2NVAyPTZ2PD;hQi=>
HeLa Kyoto	M1rCPGZ2dmO2aX;uJIF{e2G7	NGXFeWkxNjJ3IIXN	MlfKNlAhcHK\|		M{TOXWlvcGmkaYTpc44hd2ZiQYXyc5JiKEFia3nuZZNmKGyxY3HsbZpifGmxbjDheEB{eGmwZHzlJI1q[3KxdIXieYxmeyCrbjDoeY1idiCKZVzhJGt6d3SxIHPlcIx{KGG2IECuNlUhfU1iaX7jeYJifGWmIH\vdkAzOCCqcoO=	MoLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|OUGxN\|MoRjJ5M{mxNVM{RC:jPh?=
MDA-MB-231	M1vse2Z2dmO2aX;uJIF{e2G7	NWPYc\|Z4OSC3TR?=	M2LvZlQ5KGi{cx?=		M4nJVWlv\HWldHnvckBw\iClaILvcY9{d22nIHHsbYdvdWWwdDDk[YZm[3S\|IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhTEGSSTDzeIFqdmmwZzDiZZNm\CCrbX31co9ndHWxcnXzZ4Vv[2ViYYPzZZk>	MmLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|NUixOFcoRjJ7M{W4NVQ4RC:jPh?=
MDA-MB-231	MnnDSpVv[3Srb36gZZN{[Xl?	NWT5WVYxOSC3TR?=	NF32WYg1QCCqcoO=		NEn1cIVKdmS3Y4Tpc44hd2ZiYXLldpJidnRic4DpcoRt\SCob4LtZZRqd25id3n0bEB1emmyb3zhdkBidmRidHX0doFxd2yjcjDvZ4N2enKnbnPlJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZQhOSC3TTDh[pRmeiB2ODDodpMh[nliRFHQTUB{fGGrbnnu[{Bj[XOnZDDpcY12dm:obIXvdoV{[2WwY3WgZZN{[Xl?	NXvXW\|ZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzOVgyPDdpPkK5N\|U5OTR5PD;hQi=>
MDA-MB-231	NIT0O5JHfW6ldHnvckBie3OjeR?=	M4X4ZVAvPSC3TR?=	NX;ObXQ3PDhiaILz		MkHGTY5pcWKrdHnvckBw\iCjbIDoZU11fWK3bHnuJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZN{\XO\|ZXSgZZMh[WKxbHnzbI1mdnRib3[gdoVofWyjcjDsc4NifGmxbjDv[kBxem:2ZXnuJIF1KDBwNTD1UUBi\nSncjC0PEBpenNiYomgSGFRUSC\|dHHpcolv\yCkYYPl[EBqdW23bn;mcJVwemW\|Y3XuZ4Uh[XO\|YYm=	MmrlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|NUixOFcoRjJ7M{W4NVQ4RC:jPh?=
MDA-MB-231	NWnxPGRiTnWwY4Tpc44h[XO\|YYm=	NInYPXAxNjVidV2=	MYq0PEBpenN?		M4qxPWlvcGmkaYTpc44hd2ZiQWXST2EhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCjYn;sbZNpdWWwdDDv[kBz\We3bHHyJIxw[2G2aX;uJI9nKHC{b4TlbY4h[XRiMD61JJVOKGGodHXyJFQ5KGi{czDifUBFSVCLIIP0ZYlvcW6pIHLhd4VlKGmvbYXuc4ZtfW:{ZYPj[Y5k\SCjc4PhfS=>	MlrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|NUixOFcoRjJ7M{W4NVQ4RC:jPh?=
TC32	Mn\kdWhVWyCjc4PhfS=>				MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	M3HGe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	MY\xTHRUKGG\|c3H5				Mnq5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NYfPWGo3eUiWUzDhd5NigQ>?				M3[4c5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	Moq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	MVnxTHRUKGG\|c3H5				M3PSNZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	Ml\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	NHXLeGVyUFSVIHHzd4F6				NFzMWJByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	NITPSJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	NXPmSo5reUiWUzDhd5NigQ>?				NYPZTlNieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	MmfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	NF7OdVhyUFSVIHHzd4F6				MlTsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUWchPjNiKE[tWGchWiliY3XscJM>	M37lfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	M4jpWpFJXFNiYYPzZZk>				NVLaenZzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	MXvxTHRUKGG\|c3H5				M3jkbJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NGX6O2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	Mk\idWhVWyCjc4PhfS=>				MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NYDQenpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	MXHxTHRUKGG\|c3H5				MkHSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	M3jWSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MX;xTHRUKGG\|c3H5				MYnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	NYPtNIFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	MofIdWhVWyCjc4PhfS=>				MoC5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	NFTUe\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NGn4W4lyUFSVIHHzd4F6				MnHKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	M3[2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	M1\ZbJFJXFNiYYPzZZk>				MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	MkG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NEPmcm1yUFSVIHHzd4F6				M3HoUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNid3NvMjDj[Yxtew>?	MkDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AURKA(T288) / p-EIF4E(S209) / c-Myc; PubMed: 28073841 Clin Cancer Res Inhibition of AURKA with alisertib downregulated p-EIF4E (S209) and c-MYC protein levels as assayed by Western blotting. phospho-Aurora A / Aurora B; PubMed: 22863010 Cell MLN8237differentially inhibited phosphorylation of Aurora kinases. CMK cells were incubated with 0.1 µM paclitaxel for 18 hr, then DMSO or MLN8237 was added and incubated for 2 hr. The degree of phosphorylation of the Aurora kinases in each sample was determined by Western blot. H3S10P / H3K27me2 / H3K27me3 / H3K9me2 / H3AcK / H4K16Ac; PubMed: 29477140 Mol Cells THP-1 cells were treated with alisertib or DMSO for 48 h. The levels of histone modifications were detected by western blot analysis with the indicated antibodies. H3 was used as a loading control.	28073841 22863010 29477140
Growth inhibition assay	Cell viability; PubMed: 25632225 Drug Des Devel Ther PANC-1 and BxPC-3 cells were treated with ALS at concentrations ranging from 0.1 μM to 50 μM for 24 hours. The viability of PANC-1 and BxPC-3 cells determined by MTT assay. ALS, alisertib.	25632225
Immunofluorescence	acetylated α-tubulin / γ-tubulin; PubMed: 29401581 FASEB J Representative immunofluorescence (IF) image and graph in human PKD1-mutant WT9-7, WT9-12 cells or hTERT-RPE1 (RPE1) cells after 2 hours treatment with vehicle, ganetespib , or alisertib to inhibit AURKA, or combination of alisertib and ganetespib. acetylated α-tubulin (red); γ-tubulin (green); DAPI (blue). Scale bars, 5 μm. E-cadherin / β-catenin / vimentin / p-SMAD5; PubMed: 23334326 Oncogene Immunofluorescence analysis of CD24 (-/low) cells treated with1 μM MLN8237 for 48 and 72 h showing reversion of EMT. E-cadherin and p-SMAD5 were labeled in red, β-catenin and vimentin were labeled in green, and DNA was labeled in blue with Hoechst dye. Centrin-2 / tubulin; PubMed: 30899434 Oncotarget Following inhibition of Aurora A kinase activity with 100 nM alisertib, cells with two or excess centrosomes similarly exhibit disorganized mitotic spindles. Cells with extra centrosomes are efficiently clustered into bipolar spindles prior to anaphase onset while those with supernumerary centrosomes undergo multipolar mitoses. Centrin-2, a marker of centrioles is shown in green, tubulin in red, and chromatin in blue. AurA inhibitor: alisertib. phospho-Aurora A(T288); PubMed: 20382844 Blood MM1.S cells were treated with DMSO or MLN8237 (0.5μM) for 24 hours and then stained with anti-phospho (Thr288)-Aurora-A kinase antibody (red), αtubulin (green), and DNA (blue). Overlapping localization is shown in the merged images. Arrow indicates Aurora-A autophosphorylation on Thr288 in the centrosome (original magnification ×40). Magnified single mitotic cell image is shown in the right panel.	29401581 23334326 30899434 20382844

体内研究

MLN8237口服处理，显著降低肿瘤负担，按15 mg/kg 和30 mg/kg剂量处理肿瘤生长抑制率(TGI) 分别为42%和80%,且与对照组相比，延迟小鼠寿命。^[2] MLN8237 (30 mg/kg) 与Cisplatin (2 mg/kg) 联用作用于FLO-1移植瘤，与单独用药相比，抗癌活性增强，伴随着Ki-67表达受抑制，细胞核p73蛋白和cleaved caspase 3表达增强。^[3]

激酶实验：^[1]	- 合并 Aurora A放射性闪光板酶实验: 进行Aurora A放射性闪光板酶实验，测定体外MLN8237抑制程度。在Sf9细胞中表达重组Aurora A，然后使用GST亲和层析进行纯化。Aurora A 肽底物与生物素联合形成生物素-GLRRASLG。在50 mM Hepes (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 0.05% Tween-20, 2 μM 肽底物, 3.3 μCi/mL [γ-³³ P]ATP 2 μM, 和浓度不断增高的MLN8237 的混合物中进行Aurora A激酶 (5 nM)实验。
细胞实验：^[2]	- 合并 Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, 和U266 Concentrations: 溶于DMSO,终浓度为~10 μM Incubation Time: 24, 48, 和72小时 Method: 使用不同浓度MLN8237处理细胞24, 48,和72小时。通过MTT实验测定细胞活力，通过测定 3[³H]-胸甘渗透而测定细胞增殖。为了分析细胞周期，使用70%乙醇在-20^oC下使细胞通透，然后与50 μg/mL PI 和20 单位/mL RNase-A温育。通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件分析DNA含量。为了测定凋亡和衰老，使用异硫氰酸荧光素-annexin V和PI对细胞进行染色。通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件测定凋亡细胞。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: 皮下接种 MM1.S 细胞的SCID鼠 Dosages: ~30 mg/kg/day Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	27 mg/mL (52.03 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+30% PEG300+5%Tween-80+ddH2O	6mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Alisertib (MLN8237) SDF

分子量	518.92
化学式	C₂₇H₂₀ClFN₄O₄
CAS号	1028486-01-2
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04479306	Recruiting	Drug: Alisertib\|Drug: Osimertinib\|Drug: Sapanisertib	Recurrent Lung Non-Small Cell Carcinoma\|Stage IIIB Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	M.D. Anderson Cancer Center	June 18 2020	Phase 1
NCT02812056	Withdrawn	Drug: Alisertib\|Drug: TAK-228	Malignant Neoplasms of Digestive Organs\|Malignant Neoplasms of Female Genital Organs\|Malignant Neoplasms of Lip Oral Cavity and Pharynx\|Malignant Neoplasms of Male Genital Organs	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals Inc.	September 2016	Phase 1
NCT02719691	Active not recruiting	Drug: Alisertib\|Drug: MLN0128	Metastatic Breast Cancer\|Solid Tumors	University of Colorado Denver	May 13 2016	Phase 1
NCT02367352	Terminated	Drug: Alisertib\|Drug: Paclitaxel	Advanced Solid Tumors\|Ovarian Cancer\|Small Cell Lung Cancer	Millennium Pharmaceuticals Inc.\|Takeda	March 19 2015	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the suggested formulation of this compound for mouse injection(i.p.)?
回答：
It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

泛Aurora Kinase抑制剂

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
泛Aurora Kinase抑制剂

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
活性最高的Aurora Kinase抑制剂

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
用于临床的Aurora Kinase抑制剂

VX-680 (Tozasertib, MK-0457) : Phase II for Advanced Non-Small Cell Lung Cancer (NSCLC).
经典的Aurora Kinase抑制剂

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

研究领域

产品类型

定制您的化合物库

Alisertib (MLN8237)

客户使用Selleck生产的Alisertib (MLN8237)发表文献254篇：

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Alisertib (MLN8237) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

常见问题及建议解决方法

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品